Liquidia was preparing to launch a new formulation of treprostinil that represents a huge benefit to patients with PH-ILD, or pulmonary hypertension associated with interstitial lung disease. Unfortunately, patients with PH-ILD are often assessed after they have seen significant functional decline.
Discerning PH from the underlying lung disease can be difficult, because both conditions result in reduced lung function. However, dyspnea, or difficulty breathing, tends to worsen to a greater degree when PH is difficult.
By bringing worsening dyspnea to life and enabling community pulmonologists with practical assessment tools, Liqudia was able to help providers get more patients assessed for PH-ILD and prepare for their new launch.